Table 1 Baseline characteristics according to the treatment which subjects were randomized to receive during the first 10-week period of the crossover trial*

N

Age, years (mean, SD)

Sex (N, %)

 Male

 Female

Race (N, %)

 White

 African-American

 Asian

 Hispanic/Latino

Waist circumference, cm (mean, SD)

 Male

 Female

Height, meters (mean, SD)

Weight, kg (mean, SD)

Body mass index (mean, SD)

HDL-cholesterol, mg/dL (mean, SD)

 Male

 Female

LDL-cholesterol, mg/dL (mean, SD)

Triglycerides, mg/dL (mean, SD)

Fasting glucose, mg/dL (mean, SD)

SBP average clinic value, mmHg (mean, SD)

DBP average clinic value, mmHg (mean, SD)

Ambulatory blood pressure readings (mmHg)

Full 24-hour period

 Measurements per subject (mean, SD)

 Average SBP, mmHg (mean, SD)

 Average DBP, mmHg (mean, SD)

Wake period (0800 to 2200)

Measurements per subject (mean, SD)

Average SBP, mmHg (mean, SD)

Average DBP, mmHg (mean, SD)

Sleep period (2200 to 0800)

 Measurements per subject (mean, SD)

 Average SBP, mmHg (mean, SD)

 Average DBP, mmHg (mean, SD)

Subjects with each of the following MetS components (N, %)

 Waist circumference ≥102 cm (male) or ≥88 cm (female)

 HDL cholesterol <40 mg/dL (male) or <50 mg/dL (female)

 Triglycerides ≥150 mg/dL

 Fasting glucose ≥100 mg/dL

 SBP ≥130 mmHg or DBP ≥85 mmHg

Number of MetS components per subject (mean, SD)

Proportion of subjects with MetS at the time of randomization (N, %)

Proportion with different number of components of MetS (N, %)

 0

 1

 2

 3

 4

 5